These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 30691343)

  • 21. Effect of insulin degludec versus insulin glargine on glycemic control and daily fasting blood glucose variability in insulin-naïve Japanese patients with type 2 diabetes: I'D GOT trial.
    Aso Y; Suzuki K; Chiba Y; Sato M; Fujita N; Takada Y; Murano S; Kuroda H
    Diabetes Res Clin Pract; 2017 Aug; 130():237-243. PubMed ID: 28651211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application.
    Owens DR; Bolli GB
    Diabetes Technol Ther; 2008 Oct; 10(5):333-49. PubMed ID: 18715209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical use of insulin degludec.
    Vora J; Cariou B; Evans M; Gross JL; Harris S; Landstedt-Hallin L; Mithal A; Rodriguez MR; Meneghini L
    Diabetes Res Clin Pract; 2015 Jul; 109(1):19-31. PubMed ID: 25963320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different.
    Cheng AYY; Patel DK; Reid TS; Wyne K
    Adv Ther; 2019 May; 36(5):1018-1030. PubMed ID: 30929185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Will the next generation of basal insulins offer clinical advantages?
    Garber AJ
    Diabetes Obes Metab; 2014 Jun; 16(6):483-91. PubMed ID: 24118819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Old and new basal insulin formulations: understanding pharmacodynamics is still relevant in clinical practice.
    Rossetti P; Ampudia-Blasco FJ; Ascaso JF
    Diabetes Obes Metab; 2014 Aug; 16(8):695-706. PubMed ID: 24401118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Review of the Clinical Efficacy and Safety of Insulin Degludec and Glargine 300 U/mL in the Treatment of Diabetes Mellitus.
    Woo VC
    Clin Ther; 2017 Aug; 39(8S2):S12-S33. PubMed ID: 28187863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin degludec: a novel basal insulin analogue.
    Goldman-Levine JD; Patel DK; Schnee DM
    Ann Pharmacother; 2013 Feb; 47(2):269-77. PubMed ID: 23386075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use.
    Haahr H; Fita EG; Heise T
    Clin Pharmacokinet; 2017 Apr; 56(4):339-354. PubMed ID: 27696221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Understanding the Pharmacokinetics and Glucodynamics of Once Weekly Basal Insulins to Inform Dosing Principles: An Introduction to Clinicians.
    Pieber TR; Leohr J; Bue-Valleskey JM; Juneja R; Chien J; Syring K; Buse JB
    Endocr Pract; 2024 Sep; 30(9):863-869. PubMed ID: 38880349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
    Hirao K; Maeda H; Urata S; Takisawa Y; Hirao S; Sasako T; Sasaki T
    Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current Status of Weekly Insulin Analogs and Their Pharmacokinetic/Pharmacodynamic Evaluation by the Euglycemic Clamp Technique.
    An N; Wang X; He A; Chen W
    Clin Pharmacol Drug Dev; 2023 Sep; 12(9):849-855. PubMed ID: 37439495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical use of the co-formulation of insulin degludec and insulin aspart.
    Kumar A; Awata T; Bain SC; Ceriello A; Fulcher GR; Unnikrishnan AG; Arechavaleta R; Gonzalez-Gálvez G; Hirose T; Home PD; Kaku K; Litwak L; Madsbad S; Pinget M; Mehta R; Mithal A; Tambascia M; Tibaldi J; Christiansen JS
    Int J Clin Pract; 2016 Aug; 70(8):657-67. PubMed ID: 27384031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design of non-standard insulin analogs for the treatment of diabetes mellitus.
    Pandyarajan V; Weiss MA
    Curr Diab Rep; 2012 Dec; 12(6):697-704. PubMed ID: 22983891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical considerations for use of insulin degludec/insulin aspart in Japanese patients.
    Hirose T; Awata T; Yamamoto Y; Hemmingsen MP
    Expert Opin Biol Ther; 2018 Jan; 18(1):77-85. PubMed ID: 29017373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New insulin types in type 1 diabetes mellitus].
    Mesa J
    Med Clin (Barc); 2015 Jul; 145(2):70-5. PubMed ID: 25200067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concentrated insulins in current clinical practice.
    Schloot NC; Hood RC; Corrigan SM; Panek RL; Heise T
    Diabetes Res Clin Pract; 2019 Feb; 148():93-101. PubMed ID: 30583034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.
    Heise T; Hermanski L; Nosek L; Feldman A; Rasmussen S; Haahr H
    Diabetes Obes Metab; 2012 Sep; 14(9):859-64. PubMed ID: 22594461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Understanding the safety of the new ultra long acting basal insulin.
    Ramachandran A; Gupta V; Kesavadev J; Kalra S
    J Assoc Physicians India; 2014 Jan; 62(1 Suppl):35-42. PubMed ID: 25330630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin glargine 300 U/mL and insulin degludec: A review of the current evidence comparing these two second-generation basal insulin analogues.
    Cheng A; Bailey TS; Mauricio D; Roussel R
    Diabetes Metab Res Rev; 2020 Oct; 36(7):e3329. PubMed ID: 32315508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.